CJC-1295

CJC-1295 is a modified form of the active fragment of growth hormone–releasing hormone. The natural signal is destroyed within a couple of minutes by an enzyme called DPP-4, which cuts peptides at a specific point near the start of the chain. Four amino acid substitutions in CJC-1295 make that point unreadable to the enzyme, and the molecule survives instead of being dismantled on arrival.

This is why the product is offered in two forms, and the distinction is the most important thing on the page. The version without DAC is the substituted fragment alone, often called modified GRF(1-29); it resists the enzyme but is still cleared by the kidneys within about half an hour. The version with DAC carries an additional chemical group — a Drug Affinity Complex — that binds it to albumin, the abundant carrier protein in blood. Bound to albumin the peptide is too large to filter out, and its measured half-life extends from minutes to days.

Those two forms are not interchangeable and are not studied for the same thing. A short-acting analogue produces a pulse; a long-acting one produces a sustained elevation. Since growth hormone is naturally released in bursts, the choice between them determines what kind of biology an experiment is actually modelling.

• Enzyme-resistant design: The four substitutions are a textbook case of protecting a peptide by editing the site an enzyme recognises rather than by shielding the whole molecule. The same principle underlies several approved metabolic drugs.

• Albumin binding as a strategy: The DAC group works by attaching the peptide to a protein already circulating for days. Borrowing a carrier's lifespan is a general technique in peptide chemistry, and this compound is one of its clearest demonstrations.

• Pulsatile against continuous signalling: Having both forms of one molecule allows a direct comparison between a brief signal and a sustained one, with the peptide otherwise unchanged. Few compounds allow that variable to be isolated so cleanly.

• Combination pharmacology: It is frequently examined alongside peptides acting on the ghrelin receptor, because the two receptor systems converge on the same pituitary cell by separate routes and their combined effect is a real research question.

Peptides in the bloodstream are removed two ways: enzymes cut them apart, and the kidneys filter out anything small enough to pass. A peptide has to survive both to last. CJC-1295 addresses them separately, which is why it exists in two versions and why the difference between them is so large.

The substitutions deal with the enzymes. DPP-4 recognises a particular pattern at one end of the chain and cuts there; change the residues forming that pattern and the enzyme no longer sees a target. This is precise molecular editing rather than general toughening — one site, protected, and the rest of the molecule left as the receptor expects to find it.

The DAC group deals with filtration. It bonds to albumin, a protein present in blood at high concentration that stays in circulation for weeks. A peptide attached to albumin is carried as part of a much larger object and is no longer filtered, which turns minutes into days. The consequence is that the DAC form holds the GHRH signal at a steady low level, whereas the natural system operates in bursts — a genuine difference in what is being modelled, not merely a matter of convenience.

The chemistry is well supported. Early clinical studies of the DAC form measured sustained rises in growth hormone and IGF-1 over several days, confirming that the albumin strategy does what it was designed to do. The enzymatic protection conferred by the substitutions is likewise established.

Development did not continue to approval, so there is no long-term controlled human data, and it is supplied for laboratory research only. One practical point is worth knowing: the two forms are frequently conflated in secondary sources, where "CJC-1295" is used without stating which is meant. The variant name on this page says which, and having both available is what makes the pulse-against-sustained comparison possible.

In research protocols CJC-1295 appears most often beside Ipamorelin, and the two are supplied together as the CJC-1295 + Ipamorelin preparation. The rationale is mechanistic rather than promotional: they engage different receptors on the same pituitary cell, one amplifying the release signal and the other acting through the ghrelin pathway.

Sermorelin is the unmodified parent and the obvious comparator for what the substitutions achieved, while Tesamorelin solves the same stability problem on the full-length hormone. Where a study needs to attribute an effect to one of them, both are supplied separately, and a combined effect is something a combination study measures directly.